[CAS NO. 2158322-33-7]  PROTACERαDegrader-5

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2158322-33-7]

Store
Catalog
HY-112100
Brand
MCE
CAS
2158322-33-7

DESCRIPTION [2158322-33-7]

Overview

MDL-
Molecular Weight1674.93
Molecular FormulaC94H107N13O16
SMILESCN(C(COCCOCCNC(C1=CC=C(C(N2[C@@H](C)[C@H](NC([C@H](C)NC)=O)C(N(CC3=C(OC)C=CC4=C3C=CC=C4)C5=C2C=C(C#N)C=C5)=O)=O)C=C1)=O)=O)CCOC(C=C6)=CC=C6/C(C7=CC=C(OCC(C=C8)=CC=C8NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN9C(C=CC9=O)=O)=O)=O)=O)C=C7)=C(C%10=CC=CC=C%10)/CC

For research use only. We do not sell to patients.

Summary

PAC, consists the ADCs linker and PROTACs , conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).


IC50 & Target

Estrogen receptor-alpha (ERα) [1]


In Vitro

Treatment of HER2 expressing cells with HER2 antibody containing PAC Anti-HER2(Endox-XIAP) results in a marked decreased Estrogen Receptor-alpha (ERα) levels with an IC 50 of 132 ng/mL. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding group (“E3LB”), a linker (“L2”) and a protein binding group (“PB”). The following sections describe the components that comprise the PAC. To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A“linker” (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

-20°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)


Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 59.70 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.5970 mL 2.9852 mL 5.9704 mL
5 mM 0.1194 mL 0.5970 mL 1.1941 mL
10 mM 0.0597 mL 0.2985 mL 0.5970 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (1.49 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (1.49 mM); Clear solution

* All of the co-solvents are available by MCE.